40M Stock Chart & Stats
€0.25
>-€0.01(-2.14%)
At close: 4:00 PM EST
€0.25
>-€0.01(-2.14%)
Day’s Range― - ―
52-Week Range€0.12 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€67.00M
Enterprise Value€632.73
Total Cash (Recent Filing)€73.02M
Total Debt (Recent Filing)€987.00K
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding164,585,050
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€10.36M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and growing equity provide financial flexibility for continued platform development. This reduces balance-sheet stress and may help Nanexa fund operations or partnerships without relying heavily on debt.
Losses NarrowingImproving losses and a return to positive gross profit suggest that operating economics may be moving in the right direction. Although profitability remains distant, this trend could support better capital efficiency as programs mature.
PharmaShell PlatformA platform addressing long-acting delivery and dosing convenience can support multiple pharmaceutical programs rather than a single product. Partnering and licensing may create milestone and royalty opportunities if development programs advance.
Bears Say
Persistent Cash BurnDeeply negative free cash flow means Nanexa continues to consume funding while developing its technology. Sustained cash burn can require future financing, potentially creating dilution or limiting the pace of platform investment.
Ongoing UnprofitabilityThe company has not yet demonstrated a durable profitable operating model. Continued operating losses leave results dependent on future program progress, funding access and partner economics rather than established recurring earnings.
Uncertain Revenue BaseFlat-to-declining recent revenue and volatile gross margins indicate that commercial traction remains uneven. The absence of confirmed significant partnerships or a stable revenue mix increases uncertainty around the timing and quality of future cash inflows.
Nanexa AB News
40M FAQ
What was Nanexa AB’s price range in the past 12 months?
Nanexa AB lowest stock price was €0.12 and its highest was €0.43 in the past 12 months.
What is Nanexa AB’s market cap?
Nanexa AB’s market cap is €67.00M.
When is Nanexa AB’s upcoming earnings report date?
Nanexa AB’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Nanexa AB’s earnings last quarter?
Nanexa AB released its earnings results on Aug 27, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nanexa AB overvalued?
According to Wall Street analysts Nanexa AB’s price is currently Overvalued.
Does Nanexa AB pay dividends?
Nanexa AB does not currently pay dividends.
What is Nanexa AB’s EPS estimate?
Nanexa AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanexa AB have?
Nanexa AB has 164,585,050 shares outstanding.
What happened to Nanexa AB’s price movement after its last earnings report?
Nanexa AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.231%.
Which hedge fund is a major shareholder of Nanexa AB?
Currently, no hedge funds are holding shares in DE:40M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanexa AB
Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.
Technical Analysis
Camurus AB
―
Nanologica AB
―
Xspray Pharma AB
―
Spago Nanomedical AB
―
Enzymatica AB
―